Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NIH Resists “March In” On Norvir Patents Based On Pricing Concerns

This article was originally published in The Pink Sheet Daily

Executive Summary

NIH will not invoke its “march-in” authority under the Bayh-Dole Act to allow broader access to Norvir patents, Director Francis Collins says in response to a petition.

You may also be interested in...

Xtandi’s Success A Double-Edged Sword

Astellas/Medivation prostate cancer drug is the latest focus of drug pricing criticism in the news but it doesn’t seem likely that NIH will grant open licenses on the drug’s patent under its “march-in” authority, as legislators and advocacy groups request.

Clinton’s Drug Plan Embraces CER-Driven Pricing ‘Accountability’

Think tank report that informed the plan suggests impact of CER reviews could be bolstered by use of NIH "march-in" rights if prices stay "unreasonably" high despite review conclusions.

Patent March-In Power: Government Likes Having, Not Using It

GAO report concludes that although never employed, Bayh-Dole power "is particularly valuable as leverage in informal discussions."

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts